Weiss G, Thuma P E, Mabeza G, Werner E R, Herold M, Gordeuk V R
Department of Internal Medicine, University Hospital, University of Innsbruck, Austria.
J Infect Dis. 1997 Jan;175(1):226-30. doi: 10.1093/infdis/175.1.226.
To determine whether iron chelation modulates nitric oxide (NO) formation and cell-mediated immune effector function in children with cerebral malaria, serum concentrations were measured of the stable end products of NO, nitrite and nitrate (NO2-/NO3-), interleukin (IL)-4, -6, and -10, and neopterin in 39 Zambian children enrolled in a placebo-controlled trial of desferrioxamine B and quinine therapy. Mean concentrations of NO2-/NO3- increased significantly over 3 days in children receiving desferrioxamine plus quinine but not in those given placebo and quinine. Neopterin levels declined significantly with placebo but not with desferrioxamine. IL-4 levels increased progressively in the placebo group and ultimately decreased in the desferrioxamine group, but the trends were not statistically significant. IL-6 and IL-10 levels were elevated initially and decreased significantly in both groups over 3 days. These data are consistent with the hypothesis that iron chelation therapy in children with cerebral malaria strengthens Th1-mediated immune effector function involving increased production of NO.
为了确定铁螯合作用是否能调节脑型疟疾患儿的一氧化氮（NO）生成及细胞介导的免疫效应功能，在一项关于去铁胺B和奎宁治疗的安慰剂对照试验中，对39名赞比亚儿童的血清中NO稳定终产物亚硝酸盐和硝酸盐（NO2-/NO3-）、白细胞介素（IL）-4、-6、-10以及新蝶呤的浓度进行了测量。接受去铁胺加奎宁治疗的儿童，其NO2-/NO3-的平均浓度在3天内显著升高，而接受安慰剂加奎宁治疗的儿童则未出现这种情况。使用安慰剂时新蝶呤水平显著下降，而去铁胺治疗时则未下降。IL-4水平在安慰剂组中逐渐升高，在去铁胺组中最终下降，但这些趋势无统计学意义。IL-6和IL-10水平最初升高，两组在3天内均显著下降。这些数据与以下假设一致，即脑型疟疾患儿的铁螯合疗法可增强Th1介导的免疫效应功能，包括增加NO的生成。
